{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["Abatacept"], "o": []}
{"i": [], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["CTLA4"], "o": ["macrophage activation", "pro - inflammatory cytokines", "autoantibody formation"]}
{"i": ["CTLA4 antigen"], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["Abatacept"], "o": []}
{"i": [], "o": []}
{"i": ["abatacept", "MTX"], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["placebo - controlled", "Abatacept"], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["Abatacept"], "o": []}
{"i": [], "o": []}
{}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["MTX"], "o": []}
{"i": ["+ MTX PBO + MTX", "VSH", "MTX", "PBO + MTX PBO + MTX PBO + MTX"], "o": []}
{"i": ["Abatacept"], "o": ["joint damage", "structural damage"]}
{"i": ["abatacept", "methotrexate ( MTX )"], "o": ["rate of radiological progression", "radiological score ( Genant score index", "erosions"]}
{"i": [], "o": []}
{"i": ["abatacept + MTX"], "o": ["total radiological progression", "radiographic progression"]}
{"i": ["abatacept"], "o": ["rate of progression", "long - term structural progression"]}
{"i": [], "o": []}
{"i": ["abatacept", "MTX"], "o": ["total radiological progression"]}
{"i": ["abatacept", "placebo"], "o": ["rate of progression", "rates of progression"]}
{"i": ["abatacept + MTX"], "o": ["radiological progression"]}
{"i": ["MTX"], "o": ["rate of structural destruction"]}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept", "placebo", "abatacept + MTX"], "o": ["clinical efficacy and safety"]}
{"i": ["abatacept", "abatacept plus MTX", "placebo + MTX"], "o": ["osteitis", "structural damage", "progression of the erosions", "reduce synovitis"]}
{"i": [], "o": []}
{"i": ["abatacept"], "o": []}
{"i": [], "o": ["disease activity", "DAS28", "clinical benefit"]}
{"i": [], "o": ["structure of inflammatory infiltrate", "synovial joint", "expression of pro - inflammatory cytokines ( especially IFN - gamma ),", "reduced tissue perfusion and vascular permeability on MRI"]}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept + MTX to adalimumab + MTX"], "o": []}
{"i": ["abatacept plus MTX", "MTX plus adalimumab"], "o": ["ACR20 response rate"]}
{"i": ["abatacept plus MTX", "adalimumab plus MTX"], "o": ["inhibition", "total score"]}
{"i": [], "o": []}
{"i": ["abatacept", "tocilizumab", "adalimumab"], "o": []}
{"i": ["abatacept", "tocilizumab .", "adalimumab"], "o": ["clinical efficacy", "disease activity"]}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept", "tocilizumab"], "o": []}
{"i": [], "o": ["a low disease activity ( LDA ) or remission"]}
{"i": [], "o": ["LDA"]}
{"i": ["abatacept", "tocilizumab"], "o": ["disease activity"]}
{"i": [], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept"], "o": ["disease activity"]}
{"i": ["abatacept"], "o": []}
{"i": [], "o": ["clinical response and remission rates"]}
{"i": ["abatacept"], "o": ["Persistence rates"]}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept", "synthetic DMARDS"], "o": []}
{"i": ["abatacept", "MTX"], "o": []}
{"i": [], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept", "TNF - alpha"], "o": ["relapse"]}
{"i": ["abatacept"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["skin lesions"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["placebo"], "o": ["ACR20 response", "significant response"]}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept"], "o": ["efficacy and safety"]}
{"i": [], "o": ["Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score", "value of CRP [ 46 ].", "overall disease assessment by the patient"]}
{"i": ["abatacept"], "o": []}
{"i": [], "o": []}
{"i": ["abatacept", "placebo - controlled", "mycophenolate mofetil and corticosteroids"], "o": ["complete renal response )"]}
{"i": ["abatacept"], "o": ["complete response"]}
{"i": [], "o": []}
{"i": ["rituximab"], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept"], "o": ["efficacy and safety"]}
{"i": ["abatacept"], "o": ["xerostomia , glandular secretory dysfunction , and the antibody production"]}
{"i": [], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["abatacept", "placebo - controlled", "Abatacept", "placebo"], "o": []}
{"i": ["abatacept"], "o": ["adverse drug reactions ( ADRs )"]}
{"i": ["abatacept", "placebo"], "o": ["percentage of ADRs"]}
{"i": ["abatacept"], "o": ["headache and nausea ."]}
{"i": ["abatacept", "placebo"], "o": ["ADRs"]}
{"i": [], "o": ["Acute infusion - related reactions"]}
{"i": [], "o": ["hypo / hypertension , dyspnea , nausea , urticaria , flushing , cough , pruritus , rash , wheezing ."]}
{"i": ["abatacept", "placebo"], "o": ["respiratory adverse events"]}
{"i": ["abatacept", "placebo ."], "o": ["severe respiratory ADRs"]}
{"i": ["abatacept", "infliximab"], "o": ["percentage of the overall infections"]}
{"i": ["abatacept", "infliximab"], "o": ["rate of severe infections"]}
{"i": [], "o": []}
{"i": ["abatacept", "infliximab , tocilizumab", "certolizumab"], "o": ["overall risk of severe infections"]}
{"i": ["abatacept"], "o": ["Pneumonia"]}
{"i": [], "o": ["rate of occurrence"]}
{"i": ["abatacept"], "o": ["number of malignancies"]}
{"i": [], "o": ["lymphoma incidence", "lung cancer incidence"]}
{"i": ["abatacept"], "o": []}
{"i": [], "o": []}
{"i": ["abatacept"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["abatacept"], "o": ["reactivation of HBV"]}
{"i": [], "o": ["HBV reactivation"]}
{"i": ["abatacept", "prophylactic antiviral therapy"], "o": ["reactivation of hepatitis"]}
{"i": ["entecavir or tenofovir )"], "o": []}
{"i": ["antiviral therapy"], "o": []}
{"i": ["abatacept"], "o": []}
{"i": ["etanercept , infliximab , adalimumab , golimumab , certolizumab )", "ACR"], "o": []}
{"i": ["abatacept"], "o": ["immunogenicity"]}
{"i": ["abatacept"], "o": ["immunogenicity"]}
{"i": ["abatacept"], "o": ["immunogenicity"]}
{"i": ["abatacept"], "o": ["side effects", "efficiency"]}
{"i": [], "o": []}
{"i": ["abatacept"], "o": ["immunogenicity"]}
{"i": ["abatacept"], "o": []}
{"i": [], "o": ["synthesized antibodies"]}
{"i": [], "o": []}
